Sequence: e4k4-x-PLGLAG-r9-x-c
| Experiment Id | EXP001666 |
|---|---|
| Paper | Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antia |
| Peptide | dtACPP |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | DGL 50 µg/mL used in viability assay; uptake studies used 10 µg DGL/200 µL; gene-silencing studies used DGL:DNA 6:1 |
| Rna Concentration | DNA 8.33 µg/mL for RT-PCR in vitro; uptake studies used pGL2 as model DNA |
| Mixing Ratio | DGL:DNA w/w 6:1 |
| Formulation Format | PEGylated DGL nanoparticles (peptide-PEG-DGL/DNA complexes) |
| Formulation Components | Dendrigraft poly-L-lysine (DGL G3) + MAL-PEG-NHS (PEG 3500) + dtACPP peptide; complexes with plasmid shVEGF (± DOX intercalated) |
| Size Nm | 145.00 |
| Zeta Mv | 2.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U-87 MG (human malignant glioma) cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | VEGF mRNA reduced to ~31.7% of control (RT-PCR) |
| Output Units | |
| Output Notes | Cells incubated pH 6.0; compared dtACPPD/shVEGF vs CPPD/shVEGF; functional RNAi via shVEGF plasmid shown |
| Toxicity Notes | >90% viability at 50 µg DGL/mL (pH 7.4 or 6.0) |
| Curation Notes |